France Faces Medical Cannabis Shortage Amid Experimentation Challenges

France's medical cannabis experimentation program is facing significant setbacks due to a shortage of key cannabis products. The shortage was exacerbated on April 19, when the CBD:THC 20:1 oil, a recommended alternative after the most prescribed product ran out, also became unavailable. This development has raised concerns about the viability of the ongoing experimentation, which aims to assess the therapeutic potential of cannabis in treating various conditions

The shortage has left healthcare professionals in a difficult position as they struggle to provide effective treatment options for patients. Professor Authier, a key figure in the program, expressed his concerns over the situation, highlighting that the lack of available products could deter healthcare professionals from participating in the program. The shortage particularly affects patients with neuropathic pain who rely on specific cannabis formulations

The French Directorate-General of Health (DGS) has been criticized for its handling of the situation. According to Professor Authier, administrative delays in launching tenders for new suppliers contributed to the current crisis. Little Green Pharma, the Australian company supplying the oils, opted not to extend their contract after incurring significant costs over the past two years, leaving the program in a precarious state

In response to the crisis, the DGS has initiated a second call for tenders to find a new supplier for the CBD 50 oil, with a potential third tender for the 20:1 oil. This move aims to stabilize the supply chain and ensure the continuation of the medical cannabis program. A meeting scheduled for April 21 will address the status of medical cannabis, its reimbursement, and potential legalization in France

The shortage has broader implications for the future of medical cannabis in France. As the country evaluates the possibility of integrating cannabis into its healthcare system, timely decisions are necessary to prevent further setbacks. Professor Authier emphasized the importance of resolving these issues before the summer to facilitate the inclusion of cannabis in the next social security financing bill

Looking forward, the outcome of the upcoming DGS meeting will be crucial in determining the trajectory of medical cannabis in France. Stakeholders are hopeful that the government will address the administrative challenges and supply chain issues to support the program's success. The situation underscores the need for effective policy and planning to ensure the sustainability of medical cannabis initiatives